Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endopeptidase inhibitors decrease myocardial ischemia/reperfusion injury in an in vivo rabbit model

J A Schriefer1, E P Broudy, A H Hassen

  • 1Department of Pharmacology, West Virginia School of Osteopathic Medicine, Lewisburg, USA.

The Journal of Pharmacology and Experimental Therapeutics
|September 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Care management.

Outcomes management for nursing practice·2002
Same author

Health outcomes skills for care management.

Outcomes management for nursing practice·2002
Same author

Nurse case management skills required for care management.

Outcomes management for nursing practice·2002
Same author

Clinical pathways and guidelines for care management.

Outcomes management for nursing practice·2002
Same author

Inhibitors of bradykinin-inactivating enzymes decrease myocardial ischemia/reperfusion injury following 3 and 7 days of reperfusion.

The Journal of pharmacology and experimental therapeutics·2001
Same author

Barogenic rupture of the stomach--a case for non-operative management: comment.

The Australian and New Zealand journal of surgery·1998

Inhibiting specific enzymes (EP24.11 and EP24.15) protects the heart from ischemia/reperfusion injury by preserving bradykinin (BK). Combining these enzyme inhibitors offers superior protection against myocardial damage.

Area of Science:

  • Cardiovascular Physiology
  • Pharmacology
  • Biochemistry

Background:

  • Ischemia followed by reperfusion causes myocardial damage and ventricular arrhythmias.
  • Angiotensin converting enzyme inhibitors reduce these arrhythmias, potentially by affecting bradykinin (BK) metabolism.
  • EP24.11 and EP24.15 are enzymes that degrade BK.

Purpose of the Study:

  • To investigate if EP24.11 and EP24.15 inhibitors reduce ischemia/reperfusion injury.
  • To determine if this protective effect is mediated by bradykinin (BK) receptors.

Main Methods:

  • Rabbits underwent cardiac ischemia (30 min occlusion) and reperfusion (2 hr).
  • Infarct size was measured using triphenyl tetrazolium chloride staining.
  • Specific enzyme inhibitors (ramiprilat, N-[1-(R,S)-carboxy-3-phenylpropyl]-Phe-pAB, N[1-(R,S)-carboxy-3-phenylpropyl]-Ala-Ala-Phe-pAb) and a BK2 receptor antagonist (HOE 140) were administered.

Related Experiment Videos

Main Results:

  • Ramiprilat and EP inhibitors significantly reduced infarct size compared to saline.
  • A combination of all three inhibitors provided the greatest reduction in infarct size.
  • The protective effect of EP inhibitors was abolished by the BK2 receptor antagonist HOE 140.
  • Enzyme assays confirmed the presence of EP24.11 and EP24.15 in rabbit hearts.

Conclusions:

  • EP inhibitors decrease ischemia/reperfusion injury by preventing bradykinin (BK) breakdown.
  • Combined EP inhibitors offer enhanced protection against myocardial injury.
  • Bradykinin (BK) receptors mediate the protective effects of EP inhibitors during ischemia/reperfusion.